Open AccessPluripotent Stem Cells in Translation: A Food and Drug Administration‐National Institutes of Health Collaboration
Author(s) -
Kleitman Naomi,
Rao Mahendra S.,
Owens David F.
Publication year - 2013
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2013-0042
Subject(s) - food and drug administration , induced pluripotent stem cell , medicine , translational research , drug development , clinical trial , administration (probate law) , stem cell , engineering ethics , microbiology and biotechnology , medical education , pharmacology , embryonic stem cell , drug , political science , pathology , engineering , biology , biochemistry , gene , genetics , law
Recently, the U.S. Food and Drug Administration (FDA), the U.S. National Institutes of Health, and the stem cell research community have collaborated on a series of workshops that address moving pluripotent stem cell therapies into the clinic. The first two workshops in the series focused on preclinical science, and a third, future workshop will focus on clinical trials. This summary addresses major points from both of the recent preclinically focused meetings.